Rankings
▼
Calendar
FATE Q1 2023 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FATE
Fate Therapeutics, Inc.
$158M
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$59M
+220.3% YoY
Gross Profit
-$7M
-11.3% margin
Operating Income
-$29M
-48.5% margin
Net Income
-$19M
-32.0% margin
EPS (Diluted)
$-0.09
QoQ Revenue Growth
+33.0%
Cash Flow
Operating Cash Flow
-$29M
Free Cash Flow
-$32M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$630M
Total Liabilities
$153M
Stockholders' Equity
$477M
Cash & Equivalents
$42M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$59M
$18M
+220.3%
Gross Profit
-$7M
-$54M
+87.6%
Operating Income
-$29M
-$74M
+61.6%
Net Income
-$19M
-$66M
+71.3%
Revenue Segments
Upfront Fee And Equity Premium
$31M
100%
← FY 2023
All Quarters
Q2 2023 →